<DOC>
	<DOCNO>NCT01788163</DOCNO>
	<brief_summary>Interventional diagnostic , international , multicenter non-comparative study EGFR mutation status aNSCLC patient ( locally advance and/or metastatic disease ) adenocarcinoma non-adenocarcinoma histology . It conduct Asia Pacific Russia ass current status EGFR mutation testing , concordance EGFR mutation status derive tumour sample blood base circulate free DNA .</brief_summary>
	<brief_title>Asia Pacific Russia Diagnostic Study EGFR Testing</brief_title>
	<detailed_description>A diagnostic study determine prevalence EGFR mutation Asian Russian patient advance NSCLC Adenocarcinoma Non-adenocarcinoma histology</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Histological cytological confirm locally advanced NSCLC ( stage IIIA/B ) suitable curative treatment metastatic ( stage IV ) NSCLC Newly diagnose patient locally advance and/or metastatic NSCLC systemic treatment Naive ( i.e . chemotherapy EGFRTKI ) patient recurrent disease previously receive adjuvant chemotherapy ( include EGFRTKI ) Provision diagnostic cancer tissue cytology sample upon inclusion ( surgical specimen , biopsy sample , cytology sample acceptable ) Provision routine blood ( plasma ) sample China , Russia , Taiwan Korea Patients age 18 year old As judged investigator , evidence severe uncontrolled systemic disease ( e.g . unstable uncompensated respiratory , cardiac , hepatic renal disease ) Evidence significant clinical disorder laboratory find make undesirable patient participate study Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>EGFR</keyword>
	<keyword>aNSCLC</keyword>
	<keyword>mutation status</keyword>
	<keyword>diagnostic study</keyword>
	<keyword>Russia</keyword>
	<keyword>China</keyword>
	<keyword>Asia</keyword>
</DOC>